Q4 2025 Management View Jennifer Good, CEO, reported that "2025 was a major inflection point for growth at Trevi, driven by our positive data readouts in both the CORAL trial in patients with ...
Stocktwits on MSN
TRVI stock slips after company plans parallel trials in lung disease — Stifel dismisses timeline concerns
While one of the two late-stage trials will be initiated in the second quarter, the second will be kickstarted in the second half of this year, the company said. ・The company also said that it has ...
Immunology startup Parallel Bio has released a model of the human immune system that is said to capture the way immunotherapies affect the body more accurately than animals. The so-called “Clinical ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Parallel Bio, a biotech company using the immune system to cure disease, today announced the release of its Clinical Trial in a Dish for studying the efficacy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results